This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 3 of 105 for:    Acute Venous Thromboembolism

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2017 by Boehringer Ingelheim
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: October 28, 2015
Last updated: August 21, 2017
Last verified: August 2017
RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize the DVT / PE patient population. All patients with a DVT and/or PE will be enrolled for cross-sectional characterization of the VTE patient population. Objective 2 will compare the safety and effectiveness of dabigatran etexilate regimens for treatment of VTE in comparison to VKA regimens. Patients treated with dabigatran etexilate or VKA will be followed up for the occurrence of outcome events for up to one year.

Venous Thromboembolism

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Demographic information (age) for Objective 1 patients [ Time Frame: baseline ]
  • Demographic information (gender) for Objective 1 patients [ Time Frame: baseline ]
  • Major bleeding based on the International Society of Thrombosis and Haemostasis (ISTH) in Objective 2 patients [ Time Frame: 12 months ]
  • symptomatic recurrent VTE including VTE-related mortality in Objective 2 patients [ Time Frame: 12 months ]
  • Anticoagulation treatment choice for VTE for Objective 1 patients [ Time Frame: baseline ]
  • Venous thromboembolism (VTE) presentation at baseline for Objective 1 patients [ Time Frame: baseline ]

Secondary Outcome Measures:
  • Recurrent DVT and PE in Objective 2 patients [ Time Frame: 12 months ]
  • VTE-related mortality in Objective 2 patients [ Time Frame: 12 months ]
  • all-cause mortality in Objective 2 patients [ Time Frame: 12 months ]
  • Recurrent deep vein thrombosis (DVT) in Objective 2 patients [ Time Frame: 12 months ]
  • Recurrent pulmonary embolism (PE) in Objective 2 patients [ Time Frame: 12 months ]

Estimated Enrollment: 14000
Actual Study Start Date: November 5, 2015
Estimated Study Completion Date: December 31, 2018
Estimated Primary Completion Date: December 31, 2018 (Final data collection date for primary outcome measure)
Patients with acute VTE
Patients will be enrolled for cross sectional characterization of baseline characteristics
Patients treated with dabigatran for acute VTE will be followed for one year
vitamin K antagonist
Patients treated with VKA for acute VTE will be followed for one year


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acute venous thromboembolism

Inclusion criteria:

  1. Written informed consent provided by the patient in accordance with local regulations
  2. Diagnosis of an acute DVT and/or PE (For objective 1, assessment of patient for study participation should be done ideally within 14 days but not more than 6 months after diagnosis of the acute VTE. For Objective 2, patient assessment should occur ideally within 14 days but not more than 30 days from diagnosis)
  3. Age >= 18 years
  4. For Objective 2, the planned anticoagulation therapy should be for at least 3 months
  5. For Objective 2, dabigatran and vitamin K antagonist patients should be available for follow-up data collection

Exclusion criteria:

  1. Need for anticoagulation therapy for conditions other than venous thromboembolism (VTE)
  2. Current participation in a clinical trial for VTE indication or current use of an unapproved drug
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02596230

Contact: Boehringer Ingelheim Call Center 1-800-243-0127

United States, Florida
Tampa General Hospital Recruiting
Tampa, Florida, United States, 33606
United States, Georgia
Ellipsis Group Recruiting
Atlanta, Georgia, United States, 30342
United States, Texas
The University Of Texas at Houston Recruiting
Houston, Texas, United States, 77030
CHU Charleroi Recruiting
Charleroi, Belgium, 6000
H.-Hartziekenhuis Recruiting
Lier, Belgium, 2500
Centre Hospitalier Universitaire de Liège Recruiting
Liège, Belgium, 4000
Spedali Riuniti di Livorno Recruiting
Livorno, Italy, 57124
Korea, Republic of
Hallym University Sacred Heart Hospital Recruiting
Anyang-si, Korea, Republic of, 14068
Dong-A University Hospital Recruiting
Busan, Korea, Republic of, 49201
Keimyung University Dongsan Medical Center Recruiting
Daegu, Korea, Republic of, 41931
Daegu Catholic University Medical Center Recruiting
Daegu, Korea, Republic of, 42472
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 03080
Soon Chun Hyang University Hospital Seoul Recruiting
Seoul, Korea, Republic of, 04401
Kyung Hee University Hospital at Gangdong Recruiting
Seoul, Korea, Republic of, 05278
VASA-CARE, s.r.o. Recruiting
Trnava, Slovakia, 917 01
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT02596230     History of Changes
Other Study ID Numbers: 1160.188
Study First Received: October 28, 2015
Last Updated: August 21, 2017

Additional relevant MeSH terms:
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Vitamin K
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antifibrinolytic Agents
Fibrin Modulating Agents
Growth Substances
Physiological Effects of Drugs processed this record on August 22, 2017